Funding for this research was provided by:
U.S. Department of Defense (W81XWH-20-10353)
US National Cancer Institute (U54CA143803, CA163124, CA093900, CA143055)
Article History
Received: 24 June 2022
Accepted: 9 December 2022
First Online: 4 January 2023
Declarations
:
: N/A.
: N/A.
: K.J.P. discloses that he is a consultant to Cue Biopharma, Inc., an equity holder in PEEL therapeutics, and a founder and equity holder in Keystone Biopharma, Inc. S.R.A. discloses that she is an equity holder in Keystone Biopharma, Inc.